EISNERAMPER

CANCER RESEARCH INSTITUTE, INC.

FINANCIAL STATEMENTS

JUNE 30, 2019 and 2018

EisnerAmper LLP
750 Third Avenue
New York, NY 10017
T 212.949.8700
F 212.891.4100
www.eisneramper.com

INDEPENDENT AUDITORS' REPORT

Board of Trustees
Cancer Research Institute, Inc.
New York, New York

Report on the Financial Statements

We have audited the accompanying financial statements of the Cancer Research Institute, Inc. (the "Institute"), which comprise the statements of financial position as of June 30, 2019 and 2018, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

The Institute's management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the financial statements, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Cancer Research Institute, Inc. as of June 30, 2019 and 2018, and the changes in its net assets and its cash flows for the years then ended, in accordance with accounting principles generally accepted in the United States of America.

EisnerAmper LLP

EISNERAMPER LLP
New York, New York
September 26, 2019

CANCER RESEARCH INSTITUTE, INC.

Statements of Financial Position

	June 30, 2019	June 30, 2018
ASSETS		
Cash and cash equivalents	**$ 27,429,143**	$ 21,375,212
Contributions and grants receivable, net	**40,821,074**	33,417,865
Bequests receivable	**330,714**	663,323
Other receivables	**287,139**	289,677
Investments	**57,410,532**	54,795,992
Property and equipment, net	**188,896**	211,061
Prepaid expenses and other assets	**484,257**	414,264
Beneficial interest in perpetual trust	**656,339**	651,669
	$ 127,608,094	$ 111,819,063
LIABILITIES AND NET ASSETS		
Liabilities:		
Accounts payable and accrued expenses	**$ 565,250**	$ 443,818
Annuities payable	**77,291**	82,684
Grants and fellowships payable, net	**68,004,733**	58,909,145
Deferred rent	**130,936**	141,069
Refundable deposit	**31,541**	49,941
Total liabilities	**68,809,751**	59,626,657
Commitment (see Note M)		
Net assets:		
Without donor restrictions:		
Undesignated and available for general activities	**29,939,479**	27,822,424
Board-designated as endowment	**4,428,807**	4,172,232
Total net assets without donor restrictions	**34,368,286**	31,994,656
With donor restrictions:		
Purpose restrictions	**20,895,328**	16,667,691
Perpetual in nature	**3,534,729**	3,530,059
Total net assets with donor restrictions	**24,430,057**	20,197,750
Total net assets	**58,798,343**	52,192,406
	$ 127,608,094	$ 111,819,063

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

Statements of Activities

	Year Ended June 30,					
	2019			2018		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Operating support and revenues:						
Public support:						
General and trustee	**$ 7,379,565**		**$ 7,379,565**	$ 6,481,958		$ 6,481,958
Combined federal campaigns	**415,069**	**$ 100,000**	**515,069**	385,015	$ 195,660	580,675
Bequests and memorials	**3,061,390**		**3,061,390**	4,240,771		4,240,771
Special events (net of direct benefit to donors of $256,236 in 2019 and $264,146 in 2018)	**2,248,880**	**12,272**	**2,261,152**	1,814,865	40,311	1,855,176
Designated contributions (including in-kind contributions of services of $484,799 in 2019 and $501,615 in 2018)	**17,150,730**	**10,493,483**	**27,644,213**	9,710,681	1,289,909	11,000,590
Total public support	**30,255,634**	**10,605,755**	**40,861,389**	22,633,290	1,525,880	24,159,170
Operating revenues:						
Rental income (loss) (net of related expenses of $130,046 in 2019 and $99,102 in 2018)	**20,197**		**20,197**	(13,128)		(13,128)
Investment income allocation	**2,586,550**		**2,586,550**	2,304,858		2,304,858
Miscellaneous	**138,308**		**138,308**	40,026		40,026
Total operating revenues	**2,745,055**		**2,745,055**	2,331,756		2,331,756
Net assets released from restrictions	**6,378,118**	**(6,378,118)**	**0**	8,078,590	(8,078,590)	0
Total operating support and revenues	**39,378,807**	**4,227,637**	**43,606,444**	33,043,636	(6,552,710)	26,490,926
Operating expenses:						
Program services:						
Science, medical and research information, and communications	**5,187,507**		**5,187,507**	4,845,502		4,845,502
Research	**25,520,160**		**25,520,160**	21,638,503		21,638,503
Total program services	**30,707,667**		**30,707,667**	26,484,005		26,484,005
Supporting services:						
Administration	**1,471,774**		**1,471,774**	1,464,722		1,464,722
Marketing and development	**2,737,455**		**2,737,455**	2,231,545		2,231,545
Allowance for uncollectible accounts	**2,163,048**		**2,163,048**	1,390,500		1,390,500
Total supporting services	**6,372,277**		**6,372,277**	5,086,767		5,086,767
Total expenses	**37,079,944**		**37,079,944**	31,570,772		31,570,772
Change in net assets from operating activities	**2,298,863**	**4,227,637**	**6,526,500**	1,472,864	(6,552,710)	(5,079,846)
Non-operating activities:						
Net investment income in excess of investment allocation	**74,767**		**74,767**	2,557,461		2,557,461
Change in value of perpetual trust		**4,670**	**4,670**		18,871	18,871
Change in net assets	**2,373,630**	**4,232,307**	**6,605,937**	4,030,325	(6,533,839)	(2,503,514)
Net assets, beginning of year	**31,994,656**	**20,197,750**	**52,192,406**	27,964,331	26,731,589	54,695,920
Net assets, end of year	**$ 34,368,286**	**$ 24,430,057**	**$ 58,798,343**	$ 31,994,656	$ 20,197,750	$ 52,192,406

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

Statement of Functional Expenses
Year Ended June 30, 2019
(with summarized financial information for 2018)

	Program Services			Support Services			Totals	
	Science, Medical and Research Information, and Communications	Research	Total	Administration	Marketing and Development	Total	2019	2018
Fellowship program		$ 4,769,750	$ 4,769,750				$ 4,769,750	$ 5,031,698
Designated grants program		928,667	928,667				928,667	1,066,646
Clinical accelerator program		10,371,973	10,371,973				10,371,973	12,541,459
Technology Prize Award		1,000,000	1,000,000				1,000,000	600,000
CLIP grants program		2,199,770	2,199,770				2,199,770	2,398,700
STAR Program		6,250,000	6,250,000				6,250,000	
Salaries, benefits and related taxes	$ 1,793,935		1,793,935	$ 1,009,289	$ 1,732,669	$ 2,741,958	4,535,893	3,847,247
Professional fees and commissions	1,255,051		1,255,051	170,641	324,197	494,838	1,749,889	2,097,492
Printing, postage and supplies	207,308		207,308	67,403	311,355	378,758	586,066	471,304
Rent	187,306		187,306	232,396	155,345	387,741	575,047	592,659
Telephone	14,405		14,405	14,405	14,405	28,810	43,215	31,935
Advertising	301,072		301,072	449	95,777	96,226	397,298	172,656
Depreciation and amortization	15,380		15,380	9,094	15,066	24,160	39,540	40,615
Travel, catering, and related costs	1,372,567		1,372,567	10,960	319,775	330,735	1,703,302	973,158
Insurance expense				37,974		37,974	37,974	35,536
Miscellaneous	40,483		40,483	49,209	25,102	74,311	114,794	642,415
Total expenses before allowance for uncollectible accounts	5,187,507	25,520,160	30,707,667	1,601,820	2,993,691	4,595,511	35,303,178	30,543,520
Allowance for uncollectible accounts				2,163,048		2,163,048	2,163,048	1,390,500
Total expenses	5,187,507	25,520,160	30,707,667	3,764,868	2,993,691	6,758,559	37,466,226	31,934,020
Less:								
Direct benefit to donors					(256,236)	(256,236)	(256,236)	(264,146)
Rent				(130,046)		(130,046)	(130,046)	(99,102)
Total expenses per statements of activities	$ 5,187,507	$ 25,520,160	$ 30,707,667	$ 3,634,822	$ 2,737,455	$ 6,372,277	$ 37,079,944	$ 31,570,772

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

Statement of Functional Expenses
Year Ended June 30, 2018

	Program Services			Support Services			
	Science, Medical and Research Information, and Communications	Research	Total	Administration	Marketing and Development	Total	Total
Fellowship program		$ 5,031,698	$ 5,031,698				$ 5,031,698
Designated grants program		1,066,646	1,066,646				1,066,646
Clinical accelerator program		12,541,459	12,541,459				12,541,459
Technology Prize Award		600,000	600,000				600,000
CLIP grants program		2,398,700	2,398,700				2,398,700
Salaries, benefits and related taxes	$ 1,592,194		1,592,194	$ 888,614	$ 1,366,439	$ 2,255,053	3,847,247
Professional fees and commissions	1,593,872		1,593,872	219,171	284,449	503,620	2,097,492
Printing, postage and supplies	160,712		160,712	85,536	225,056	310,592	471,304
Rent	203,823		203,823	211,505	177,331	388,836	592,659
Telephone	10,645		10,645	10,645	10,645	21,290	31,935
Advertising	119,380		119,380	129	53,147	53,276	172,656
Depreciation and amortization	17,059		17,059	9,341	14,215	23,556	40,615
Travel, catering, and related costs	663,963		663,963	15,692	293,503	309,195	973,158
Insurance expense				35,536		35,536	35,536
Miscellaneous	483,854		483,854	87,655	70,906	158,561	642,415
Total expenses before allowance for uncollectible accounts	4,845,502	21,638,503	26,484,005	1,563,824	2,495,691	4,059,515	30,543,,520
Allowance for uncollectible accounts				1,390,500		1,390,500	1,390,500
Total expenses	4,845,502	21,638,503	26,484,005	2,954,324	2,495,691	5,450,015	31,934,020
Less:							
Direct benefit to donors					(264,146)	(264,146)	(264,146)
Rent				(99,102)		(99,102)	(99,102)
Total expenses per statements of activities	$ 4,845,502	$ 21,638,503	$ 26,484,005	$ 2,855,222	$ 2,231,545	$ 5,086,767	$ 31,570,772

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

Statements of Cash Flows

	Year Ended June 30, 2019	Year Ended June 30, 2018
Cash flows from operating activities:		
Change in net assets	**$ 6,605,937**	$ (2,503,514)
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Donated securities	**(139,340)**	(199,613)
Proceeds from sale of donated securities	**137,039**	197,583
Depreciation and amortization	**39,540**	40,615
Allowance for uncollectible accounts	**2,163,048**	1,390,500
Net realized and unrealized gains on investments	**(2,578,661)**	(4,665,447)
Change in value of beneficial interest in perpetual trust	**(4,670)**	(18,871)
Deferred rent	**(10,133)**	141,069
Changes in:		
Contributions and grants receivable, net	**(9,566,257)**	6,835,535
Bequests receivable	**332,609**	267,798
Other receivables	**2,538**	(34,246)
Prepaid expenses and other assets	**(69,993)**	196,102
Accounts payable and accrued expenses	**116,039**	8,761
Grants and fellowships payable	**9,095,588**	4,106,072
Refundable deposits	**(18,400)**	
Net cash provided by operating activities	**6,104,884**	5,762,344
Cash flows from investing activities:		
Purchases of office equipment	**(17,375)**	(226,036)
Purchases of long-term investments	**(6,981,283)**	(11,458,507)
Proceeds from sales of long-term investments	**6,947,705**	11,383,128
Net cash provided by (used) in investing activities	**50,953**	(301,415)
Net increase in cash and cash equivalents	**6,053,931**	5,460,929
Cash and cash equivalents, beginning of year	**21,375,212**	15,914,283
Cash and cash equivalents, end of year	**$ 27,429,143**	$ 21,375,212
Supplemental disclosure of cash flow information:		
Donated services	**$ 484,799**	$ 501,615

See notes to financial statements.

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES

[1] The Institute:

The Cancer Research Institute, Inc. (the "Institute") was founded in 1953 in New York to foster the field of cancer immunology, in the belief that the body's immune system can be used to control and cure cancer. The Institute supports research with the immediate aim of increasing the understanding of the immune system and with the ultimate goal of developing immunological methods for the prevention and treatment of human cancer. The Institute also functions as a definitive source of public information on cancer immunology and cancer treatment.

The Institute is a not-for-profit corporation exempt from federal income taxes pursuant to Section 501(c)(3) of the U.S. Internal Revenue Code (the "Code") and from state and local taxes under comparable laws.

[2] Basis of accounting:

The financial statements of the Institute have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") as applicable to not-for-profit organizations.

[3] Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, public support and revenues and expenses, as well as the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

[4] Operating measure:

Operating revenues and expenses reflect the activities in which the Institute typically engages to fulfill its mission. The Institute utilizes a spending rate in making its annual investment allocation for support of operations. Investment income, including net realized and unrealized gains and losses, earned in excess of or less than the Institute's spending rate as well as the change in the value of perpetual trust is recognized as non-operating revenue.

[5] Cash and cash equivalents:

For financial reporting purposes, the Institute considers all highly liquid instruments purchased with a maturity of three months or less, when purchased, to be cash equivalents, except for those cash equivalent assets held as part of the investment portfolio.

[6] Investments:

The Institute's investments in equity securities, mutual funds, and fixed income securities are reported at their fair values in the statements of financial position based on quoted market prices. Cash equivalents held as part of the investment portfolio are also included in the balances reported as investments.

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Investments: (continued)

The Institute also has investments in limited partnerships and limited liability companies which are considered to be alternative investments, for which readily determinable fair values do not exist. The fair value of the alternative investments has been estimated based on the respective net asset value ("NAV") per share (or its equivalent unit) of each investment, as reported by the particular investment manager. Investments in limited partnerships and/or limited liability companies where NAV cannot be used as a practical expedient to fair value are valued based on the valuation policies and procedures of the general partners. The general partners perform oversight of the underlying positions, both on an investment level and from a risk perspective. The general partners are also responsible for ensuring that the investments are valued according to the policies and procedures adopted by the partnerships. The Institute places reliance upon those procedures, and it records those investments at fair value as determined by the general partners. Because of the complex management structures and nature of the underlying investments and the inherent uncertainty of the valuation of the alternative investments, the Institute's management and its various investment managers monitor their positions to reduce the risk of potential losses due to changes in fair values or the failure of counterparties to perform on a routine basis. Management believes the carrying amount of the investments in non-publicly traded securities is a reasonable estimate of their fair value. However, such estimated fair values may differ significantly from the values that would have been used had a ready market for these investments existed.

The Institute's investments, in general, are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment vehicles, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

Certain of the Institute's investment managers enter into derivatives contracts held or issued for trading purposes. These investments are subject to various market risks, which arise from changes in securities values and other market conditions. As part of their overall trading strategies, the investment managers may engage in the purchases and sales of index and equity options, for the purpose of generating profit and/or reducing market risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

Investment transactions are recorded on a trade-date basis. Realized gains and losses on investments sold, and unrealized appreciation and depreciation on investments held, are reported in the statements of activities as increases or decreases in net assets without donor restrictions unless their use is restricted through donor stipulation. Realized gains and losses on investments are determined by comparison of the cost basis to proceeds at the time of disposition. Distributions from limited partnerships and limited liability companies that represent returns of contributed capital reduce the cumulative costs basis of the respective investment. Distributions received from limited partnerships and limited liability companies in excess of the Institute's cumulative cost basis are recognized as realized gains. Unrealized gains and losses on investments are determined by comparing the investment's cost to the fair value at the end of each year. The earnings from dividends and interest are recognized when earned.

Donated securities are recorded at their estimated fair values, or by their net asset values as determined by the Institute's management on the dates of donation. The Institute's policy is to sell the donated securities immediately, and, accordingly, for purposes of the statement of cash flows, donated securities and the proceeds generated from their sale are included within operating activities. With respect to donors' contributions of equity securities, which for example, are (i) not readily marketable, (ii) the securities of private companies, or (iii) the securities of companies in liquidation, the Institute's policy is to record such items at appraised value at time of donation in the absence of readily determinable fair values, although such assets may have significant value.

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Investments: (continued)

Investment expenses include the services of bank trustees, investment managers and custodians. The balances of investment management fees disclosed in Note C are those specific fees charged by the Institute's various investment managers in each fiscal year; however, they do not include those fees that are embedded in various other investment accounts and transactions.

[7] Office equipment and leasehold improvements:

Office equipment and leasehold improvements are stated at their original costs at the dates of acquisition, or if contributed, at their fair values at the dates of donation, net of accumulated depreciation. The Institute capitalizes items of property and equipment that have a useful life greater than one year, whereas minor costs of repairs and maintenance are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of three to ten years. Leasehold improvements are recorded at cost and are amortized over the life of the lease.

Management evaluates the recoverability of the investment in long-lived assets on an on-going basis and recognizes any impairment in the year of determination. Long-lived assets were tested for impairment as of June 30, 2019 and 2018, respectively, and in the opinion of management, there were no impairments. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

[8] Beneficial interest in perpetual trust

The Institute has been named as a beneficiary of a perpetual charitable trust which is administered by a third-party trustee. The trust was created independently by a donor and is administered by an outside agent designated by the donor; accordingly, the Institute has neither possession nor control over the assets of the trust.

The Institute reported the asset and recognized contribution revenue with donor restriction-perpetual in nature, at the fair value of the Institute's interest in the trust assets. Distributions received on the trust assets are reported as revenue without donor restrictions in the statements of activities, in accordance with donor intent. Subsequent changes in fair value of the perpetual trust assets are recorded as a change in the value of perpetual trust in net assets with donor restrictions.

[9] Deferred rent:

Rent expense is recorded on a straight-line basis over the term of the lease, and includes any concession and rent escalations over the life of the lease agreement. The difference between rental payments made under the terms of the lease agreement and rent expense calculated on a straight-line basis is recorded as a deferred rent liability and included in accounts payable and accrued expenses in the statements of financial position.

[10] Accrued vacation:

Based on their tenure, the Institute's employees are entitled to be paid for unused vacation time if they leave the Institute's employ. Accordingly, at each fiscal year-end, the Institute must recognize a liability for the amount that would be incurred if employees with such unused vacation time were to leave. At June 30, 2019 and 2018, this accrued vacation obligation was approximately $240,000 and $203,000, respectively.

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[11] Functional allocation of expenses:

The costs of providing the Institute's various programs and supporting services have been summarized on a functional basis in the statements of functional expenses. Accordingly, direct costs have been functionalized within the program and supporting services based on the nature of the expense. Indirect costs have been allocated based on the basis of time and effort by employees, and square footage.

[12] Income tax uncertainties:

The Institute follows the provisions of the Financial Accounting Standards Board's (the "FASB") Accounting Standards Codification ("ASC") Topic 740, *Income Taxes*, relating to accounting and reporting for uncertainty in income taxes. For the Institute, these provisions could be applicable to the incurrence of unrelated business income. Because of the Institute's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Institute's financial statements.

[13] Net assets:

The net assets of the Institute and changes therein are reported as follows:

(i) Net Assets Without Donor Restrictions:

The Institute's net assets without donor restrictions represent those resources that are not subject to donor restrictions as to their use and are available for current operations. Funds designated by the Board of Trustees are to function as an endowment and remain without restrictions, subject to the discretion of the Board of Trustees.

(ii) Net Assets With Donor Restrictions:

Net assets with donor restrictions represent those resources that are subject to donor-imposed restrictions, such as specific purposes and/or the passage of time. Also included in net assets with donor restrictions are donor restrictions that are perpetual in nature and are subject to the requirements of the New York Prudent Management of Institutional Funds Act ("NYPMIFA"). These donors have stipulated that those resources be maintained in perpetuity with the resultant income and net capital appreciation arising from the underlying assets to be used in the satisfaction of the wishes of those donors. When a donor's restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished or a Board appropriation has been made, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as "net assets released from restrictions." Contributions with donor restrictions received in a fiscal period during which the underlying restrictions are also met within the same fiscal period are recorded as net assets without donor restrictions in the statements of activities.

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[14] Contributions:

Contributions to the Institute are recognized as revenue upon the receipt of either cash, other assets, or of unconditional pledges. Contributions are recorded as with donor restrictions if they are received with donor stipulations or time considerations as to their use. Gross proceeds paid by attendees at special events held as fundraising activities represent contribution revenue as well as the payment of the direct cost of the benefit received by the attendee at the event. Special-event income is reported net of the direct benefit to donors. Special event revenues, other than contributions, applicable to a current year are recognized as revenue in the year the special event takes place. Special event revenue for a future year's period is deferred and recognized when the event takes place. Conditional contributions are recognized when the donor's conditions have been met by requisite actions of the Institute's management or the necessary events have taken place, and if received in advance, are recognized in the statements of financial position as funds received in advance. The Institute records bequest income at the time it has an established right to a bequest and the proceeds are measurable. Contributions to be received over periods longer than a single year are discounted at an interest rate commensurate with the risk involved.

Contributions for clinical studies are recognized and recorded when the Institute recognizes the related expenses associated with the medical partners.

The Institute has entered into various clinical research support agreements to conduct clinical trials of cancer immunotherapies. The clinical trials are co-funded by various parties who have provided support in the amount of approximately $8,017,216 through June 30, 2019.

[15] Contributed services:

For recognition of contributed services in the financial statements, such services must (i) create or enhance non-financial assets, (ii) typically need to be acquired not provided by donation, (iii) require specialized skills and (iv) be provided by individuals possessing these skills. Contributed services are recorded at their estimated fair value at the dates of donation and are reported as without donor restrictions in the statements of activities. The fair values of contributed services provided by the Institute's Scientific Advisory Council totaled $484,799 and $501,615 for fiscal-years 2019 and 2018, respectively, and these amounts have been recorded as revenue and expense in the statements of activities. Other contributed services provided to the Institute such as those provided by volunteers, are not reported in the financial statements because they do not meet the criteria for recognition.

[16] Bequests:

The Institute is a beneficiary under various wills and agreements, the total realizable amounts of which are not presently determinable. The Institute's interest in bequests is recorded as revenue when the Institute receives notice that any such interest has become unconditional.

Bequests receivable were $330,714 and $663,323 as of June 30, 2019 and June 30, 2018, respectively. All amounts are due within one year. Based on management's past experience the receivables are expected to be fully collected, and, accordingly no allowance for doubtful accounts has been established.

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[17] Fellowships, investigatorships, and grants:

The Institute awards fellowships, investigatorships, and grants covering periods of one to four years for the purpose of medical research. These awards are recorded as expenses at the time they become unconditional.

[18] Science, medical and research information, and communications:

Science, medical and research information, and communications include costs primarily related to (i) providing the public with information concerning cancer immunology, (ii) responding to inquiries from the public concerning cancer, and (iii) communicating with applicants and awardees.

[19] Advertising costs:

The Institute expenses the costs of advertising as incurred. Advertising expenses were $397,298 and $172,656 during fiscal-year 2019 and 2018, respectively.

[20] Adoption of accounting pronouncement:

In August 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities*. ASU 2016-14 amends financial-statement presentations and disclosures. ASU 2016-14 includes qualitative and quantitative requirements in the following areas: (i) net asset classifications, (ii) investment returns, (iii) expense categorizations, and (iv) liquidity and availability of resources. ASU 2016-14 is effective for reporting periods issued for years beginning after December 15, 2017. Accordingly, the Institute was required to adopt ASU 2016-14 for its fiscal-year-ended June 30, 2019, which under U.S. GAAP is a change in accounting principle requiring retroactive application in the financial statements of certain areas whereas other areas are to be adopted on a prospective basis. Although the Institute's adoption of ASU 2016-14 had no effect on the Institute's total net assets or its changes in net assets for 2019 and 2018, certain reclassifications were required. Accordingly, the Institute changed its presentation of its net asset classes and added certain footnote disclosures.

[20] Subsequent events:

The Institute evaluated subsequent events through September 26, 2019, the date on which the financial statements were available to be issued.

NOTE B - CONTRIBUTIONS AND GRANTS AND OTHER RECEIVABLES

[1] Contributions and grants receivable:

At each fiscal year-end, contributions and grants receivable are estimated to be received as follows:

	June 30,	
	2019	**2018**
Gross amounts due in:		
Less than one year	**$ 15,544,043**	$ 13,734,906
One to five years	**26,305,137**	20,631,088
	41,849,180	34,365,994
Reduction for contributions due in excess of one year, at a 1% discount rate	**(528,106)**	(448,129)
	41,321,074	33,917,865
Allowance for uncollectible accounts	**(500,000)**	(500,000)
	$ 40,821,074	$ 33,417,865

An amount of approximately $33,785,720 (81%) of the outstanding pledge receivable balance at June 30, 2019 was due from three donors. Likewise, approximately $27,862,690 (83%) of the outstanding pledge receivable balance at June 30, 2018, was due from two donors. Included in contribution revenue for fiscal-year 2019, was an amount of $17,634,069 from two donors, which represented approximately 40% of the total operating support and revenue for that fiscal year.

[2] Other receivables:

At each year-end, other receivables consisted of amounts due to the Institute for exchange-type transactions. All amounts are due within one year. Based on management's past experience, these receivables are expected to be fully collected, and, accordingly, no allowance for doubtful accounts has been established.

NOTE C - INVESTMENTS

At each fiscal year-end, investments consisted of the following:

	June 30,			
	2019		**2018**	
	Fair Value	**Cost**	**Fair Value**	**Cost**
Cash equivalents	**$ 804,204**	**$ 804,204**	$ 1,642,060	$ 1,642,060
Equity securities	**2,346,778**	**2,066,086**	2,147,281	1,965,860
Mutual funds - equity securities	**2,532,715**	**2,213,996**	2,958,753	2,796,366
Mutual funds - fixed-income	**3,052,722**	**2,981,745**	1,467,816	1,326,505
Mutual funds - ETFs	**5,354,111**	**4,889,210**	5,916,807	5,310,661
Limited partnerships [a]	**43,320,002**	**30,116,006**	40,663,275	28,936,938
	$ 57,410,532	**$ 43,071,247**	$ 54,795,992	$ 41,978,390

NOTE C - INVESTMENTS (CONTINUED)

[a] The limited partnerships consist of hedge funds, private equities, and fund-of-funds that primarily invest in domestic and international securities, derivative contracts, and other investments across various classes, sectors, and geographies.

At June 30, 2019, concentrations of the Institute's investments in excess of 10% of the fair value of its portfolio included approximately 75% invested in limited partnerships.

During each fiscal year, the net investment return from investments and its classification in the accompanying statements of activities was as follows:

	Year Ended June 30, 2019	Year Ended June 30, 2018
Interest and dividends	$ 420,877	$ 334,392
Net realized and unrealized gains	2,556,733	4,665,447
Investment advisory fees	(316,293)	(137,520)
	2,661,317	4,862,319
Less: Net investment allocation for current operations	(2,586,550)	(2,304,858)
Net investment income in excess of investment allocation	$ 74,767	$ 2,557,461

The FASB's ASC Topic 820, *Fair Value Measurements*, establishes a three-level valuation hierarchy of fair-value measurements. These valuation techniques are based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair-value hierarchy:

Level 1: Valuations are based on observable inputs that reflect quoted market prices in active markets for identical investments, at the reporting date.

Level 2: Valuations are based on (i) quoted prices for similar investments in active markets, or (ii) quoted prices for those investments, or similar investments, in markets that are not active, or (iii) pricing inputs other than quoted prices that are directly or indirectly observable at the reporting date.

Level 3: Valuations are based on pricing inputs that are unobservable and include situations where there is little, if any, market activity for the investments, or the investments cannot be independently valued.

Certain of the Institute's investments are valued using NAV per share (or its equivalent unit) as a practical expedient of fair value. This applies to investments (i) which do not have a readily determinable fair value and (ii) the financial statements of which were prepared by the respective investment managers, in a manner consistent with the measurement principles of either an investment company or an entity which has the attributes of an investment company. Investments that are valued using NAV per share (or its equivalent unit) are not required to be categorized within the fair-value hierarchy, and accordingly, these NAV-investments have been appropriately excluded from the fair-value hierarchy.

NOTE C - INVESTMENTS (CONTINUED)

The availability of relevant market data is monitored by the Institute's management to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one level to another. In such instances, the transfer is reported at the beginning of the reporting period. During fiscal-years 2019 and 2018, there were no transfers among the fair-value hierarchy levels.

The following tables summarize the fair values of the Institute's investments and other assets at each fiscal year-end, in accordance with ASC Topic 820 valuation fair-value levels:

	June 30, 2019				
	Amounts Within Fair Value Hierarchy				
	Level 1	Level 3	Total	Measured at NAV	Total
Investments:					
Cash equivalents	**$ 804,204**		**$ 804,204**		**$ 804,204**
Equity securities	**2,346,778**		**2,346,778**		**2,346,778**
Mutual funds - equity securities	**2,532,715**		**2,532,715**		**2,532,715**
Mutual funds - fixed-income	**3,052,722**		**3,052,722**		**3,052,722**
Mutual funds - ETFs	**5,354,111**		**5,354,111**		**5,354,111**
Limited partnerships		**$ 955,981**	**955,981**	**$ 42,364,021**	**43,320,002**
	14,090,530	**955,981**	**15,046,511**	**42,364,021**	**57,410,532**
Other assets:					
Beneficial interest in perpetual trust		**656,339**	**656,339**		**656,339**
Total	**$ 14,090,530**	**$ 1,612,320**	**$ 15,702,850**	**$ 42,364,021**	**$ 58,066,871**

	June 30, 2018				
	Amounts Within Fair Value Hierarchy				
	Level 1	Level 3	Total	Measured at NAV	Total
Investments:					
Cash equivalents	$ 1,642,060				$ 1,642,060
Equity securities	2,147,281				2,147,281
Mutual funds - equity securities	2,958,753				2,958,753
Mutual funds - fixed-income	1,467,816				1,467,816
Mutual funds - ETFs	5,916,807				5,916,807
Limited partnerships		$ 1,165,899	$ 1,165,899	$ 39,497,376	40,663,275
	14,132,717	1,165,899	15,298,616	39,497,376	54,795,992
Other assets:					
Beneficial interest in perpetual trust		651,669	651,669		651,669
Total	$ 14,132,717	$ 1,817,568	$ 15,950,285	$ 39,497,376	$ 55,447,661

NOTE C - INVESTMENTS (CONTINUED)

The following tables summarize the changes in fair values of the Institute's Level 3 investments and other assets during each fiscal year:

	Limited Partnerships	Beneficial Interest in Perpetual Trust
Balance - June 30, 2017	$ 1,380,778	$ 632,798
Net purchases	122,251	
Net sales	(377,966)	
Net realized and unrealized losses	40,836	
Change in value		18,871
Balance - June 30, 2018	1,165,899	651,669
Net purchases	84,880	
Net sales	(353,292)	
Net realized and unrealized losses	58,494	
Change in value		4,670
Balance - June 30, 2019	$ 955,981	$ 656,339

The following table lists investments in other investment companies by major category at June 30, 2019:

	Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity funds	$ 13,003,593	$ 11,860,650	N/A	N/A
Multiple hedge funds	4,394,959		Quarterly	30-60 Days
Multiple hedge fund	9,274,376		Monthly	30-90 Days
Fund-of-funds	11,927,994		Quarterly	95 Days
Fund-of-funds	4,719,080		Monthly	95 Days
	$ 43,320,002	$ 11,860,650		

NOTE C - INVESTMENTS (CONTINUED)

Quantitative information regarding unobservable inputs developed by the Institute and assumptions used to measure the investments in limited partnerships, and the beneficial interest in perpetual trust as of June 30, 2019 are as follows:

Type	Fair Value	Valuation Techniques	Significant Unobservable Inputs	Range
Limited partnerships	**$ 955,981**	Market approach through valuation of underlying securities	Fair value of trust investment assets	N/A
Beneficial interest in perpetual trust	**$ 656,339**	Market approach through valuation of underlying securities	Fair value of trust assets	N/A

The Institute is the irrevocable beneficiary of a perpetual trust, which has been established by a donor to provide income to the Institute with income in perpetuity. At June 30, 2019 and 2018, the fair value of this trust was $656,339 and $651,669, respectively.

NOTE D - PROPERTY AND EQUIPMENT

At each fiscal year-end, property and equipment consisted of the following:

	June 30, 2019	June 30, 2018
Office equipment	**$ 486,061**	$ 476,546
Leasehold improvements	**91,569**	91,569
	577,630	568,115
Less accumulated depreciation and amortization	**(388,734)**	(357,054)
	$ 188,896	$ 211,061

During fiscal-years 2019 and 2018, the Institute disposed of fully depreciated assets that were no longer in service with a cost basis of $7,860 and $403,656, respectively.

NOTE E - GRANTS AND FELLOWSHIPS PAYABLE

At each fiscal year-end, grants and fellowships payable consisted of the following:

	June 30, 2019	June 30, 2018
Due to be paid within one years	**$ 30,217,434**	$ 30,888,428
Due to be paid between two and five years	**38,411,546**	28,380,703
	68,628,980	59,269,131
Less present value discount of 1% to 2%	**(624,247)**	(359,986)
	$ 68,004,733	$ 58,909,145

NOTE F - NET ASSETS WITH DONOR RESTRICTIONS

At each fiscal year-end, net assets with donor restrictions consisted of the following:

	June 30, 2019	June 30, 2018
Purpose restricted:		
Clinical and laboratory research	**$ 20,795,328**	$ 16,472,031
Combined federal campaign restricted for future periods	**100,000**	195,660
	20,895,328	16,667,691
Perpetual in nature:		
Fellowships	**2,878,390**	2,878,391
Other	**656,339**	651,668
	3,534,729	3,530,059
	$ 24,430,057	$ 20,197,750

Included in net assets with donor restrictions for clinical and laboratory research is accumulated endowment income reserved for appropriation at both June 30, 2019 and 2018 of $237,406.

Net assets released from restrictions during each year were for the following:

	Year Ended June 30, 2019	Year Ended June 30, 2018
Clinical and laboratory research	**$ 6,182,458**	$ 7,757,661
Combined federal campaign restricted for future periods	**195,660**	320,929
	$ 6,378,118	$ 8,078,590

NOTE G - ACCOUNTING AND REPORTING FOR ENDOWMENTS

[1] The endowment:

The Institute's endowment consists of individual funds established for a variety of purposes, consisting of both donor-restricted and Board-designated funds. As required by U.S. GAAP, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

[2] Interpretation of relevant law:

As discussed in Note A[13] (ii), NYPMIFA is applicable to all of the Institute's institutional funds, including its donor-restricted endowment funds. The Board of Trustees will continue to adhere to NYPMIFA's requirements.

[3] Endowment net-asset composition by type of fund, as of each fiscal year-end:

	June 30, 2019			
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Donor-restricted endowment funds		$ 237,406	$ 3,534,729	$ 3,772,135
Board-designated endowment funds	$ 4,428,807			4,428,807
Total funds	$ 4,428,807	$ 237,406	$ 3,534,729	$ 8,200,942

	June 30, 2018			
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Donor-restricted endowment funds		$ 237,406	$ 3,530,059	$ 3,767,465
Board-designated endowment funds	$ 4,172,232			4,172,232
Total funds	$ 4,172,232	$ 237,406	$ 3,530,059	$ 7,939,697

NOTE G - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[4] Changes in endowment net assets, during each fiscal year:

	Year Ended June 30, 2019			
	Without Donor Restrictions	**Amounts Subject to Appropriation**	**Amounts Held in Perpetuity**	**Total**
Endowment net assets, beginning of year	**$ 4,172,232**	**$ 237,406**	**$ 3,530,059**	**$ 7,939,697**
Investment return:				
Investment income	**24,353**	**20,917**		**45,270**
Net appreciation (realized and unrealized)	**198,488**	**129,509**	**4,670**	**332,667**
Total investment return	**222,841**	**150,426**	**4,670**	**377,937**
Contributions	**33,734**			**33,734**
Appropriation of endowment assets for expenditure endowment funds		**(150,426)**		**(150,426)**
Endowment net assets, end of year	**$ 4,428,807**	**$ 237,406**	**$ 3,534,729**	**$ 8,200,942**

	Year Ended June 30, 2018			
	Without Donor Restrictions	**Amounts Subject to Appropriation**	**Amounts Held in Perpetuity**	**Total**
Endowment net assets, beginning of year	$ 3,738,576	$ 237,406	$ 3,511,188	$ 7,487,170
Investment return:				
Investment income	23,110	19,705		42,815
Net appreciation (realized and unrealized)	382,646	224,399	18,871	625,916
Total investment return	405,756	244,104	18,871	668,731
Contributions	27,900			27,900
Appropriation of endowment assets for expenditure endowment funds		(244,104)		(244,104)
Endowment net assets, end of year	$ 4,172,232	$ 237,406	$ 3,530,059	$ 7,939,697

Amounts subject to appropriation represent that portion of allocated investment income, derived from endowment assets held in perpetuity, that has not yet been appropriated for expenditure by the Board of Trustees.

NOTE G - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[5] Funds with deficiencies:

Due to unfavorable market fluctuations, from time to time, the fair value of assets associated with individual donor-restricted endowment funds may decline below the historic dollar-value of the donor's original restricted contribution to be held in perpetuity. Under the terms of NYPMIFA, the Institute has no responsibility to restore such decreases in value. There were no such deficiencies at June 30, 2019 and 2018.

[6] Return objectives and risk parameters:

The Institute has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs and other functions supported by its Board-designated endowment, while seeking to maintain the purchasing power of the Board-designated endowment assets. Under this policy, as approved by the Board of Trustees, the Board-designated endowment assets are invested in a manner that is intended to produce results that obtain a better rate of return than the major investment indexes. The two donor-restricted funds (other than the perpetual trust) generate income that is fully utilized each year for their specified programmatic activities.

[7] Strategies employed for achieving objectives:

To satisfy its long-term rate-of-return objectives, the Institute relies on a total-return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Institute targets a diversified asset allocation within prudent risk constraints.

[8] Spending policy and related objectives:

(i) Endowment appropriation:

The appropriation from the endowment is based on the earnings in the respective year.

(ii) Investment pool appropriation:

The Board of Trustees' authorized spending from the Institute's investment pool (for restricted funds and for general operations) is to be limited to 5% of the average market value of the Institute's investment portfolio over the preceding three years. In establishing this policy, the Institute considered the long-term expected return on its investment. Accordingly, over the long term, the Institute expects the current spending policy to allow its portfolio to maintain the purchasing power of the Board-designated endowment assets, as well as to provide additional real growth through investment returns.

NOTE H - LIQUIDITY AND AVAILABILITY OF RESOURCES

The following reflects the Institute's financial assets as of the statement of financial position date, reduced by amounts not available for general use within one year of June 30, 2019 because of contractual or donor-imposed restrictions or internal designations. Amounts not available include amounts set aside by the Board of Trustees for the growth and sustainability of the Institute that could be drawn upon if the Board of Trustees approves the action.

The Institute's financial assets available for general use within one year of the statements of financial position date for general expenditure are as follows:

Cash and cash equivalents	$ 27,429,143
Contributions and grants receivable, net	40,821,074
Bequests receivable	330,714
Other receivables	287,139
Investments	44,406,939
Beneficial Interest in perpetual trust	656,339
Total financial assets available within one year	113,931,348
Less:	
Amounts unavailable for general expenditures within one year, due to:	
Restrictions by donors with purpose restrictions	(20,895,328)
Restricted by donors that are perpetual in nature	(3,534,729)
Total amounts unavailable for general expenditure within one year	(24,430,057)
Amounts unavailable to management without Board approval:	
Board-designated endowment	(4,428,807)
Total financial assets available to meet cash needs for general expenditures within one year	$ 85,072,484

Liquidity policy:

The Institute has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Additionally, the Institute has a Board-designated endowment whereby amounts could be made available for current operations, if necessary; however, the Institute does not intend to spend these funds for purposes other than those approved by the Board of Trustees.

NOTE I - ALLOCATION OF JOINT COSTS OF INFORMATION MATERIALS

The Institute incurred joint costs in the placement of advertisements that amounted to $57,430 and $33,630 in fiscal-years 2019 and 2018, respectively. The Institute allocated such costs as follows:

	June 30,	
	2018	**2017**
Marketing and development	**$ 34,368**	$ 16,814
Science, medical and research information and communications	**23,062**	16,816
	$ 57,430	$ 33,630

NOTE J - EMPLOYEE-BENEFIT PLAN

The Institute has a defined-contribution retirement plan, which provides for the Institute to make monthly contributions of at least 5% of the compensation of eligible employees. In addition, the Institute may contribute to the plan a discretionary amount equal to a percentage of compensation which is to be determined each plan-year by the Institute. The plan also allows the participants to make voluntary contributions up to the maximum allowed by federal tax law. During fiscal-years 2019 and 2018, the Institute contributed amounts of approximately $280,000 and $232,000, respectively, to the plan.

NOTE K - CREDIT RISK

Financial instruments that potentially subject the Institute to concentrations of credit risk consist principally of cash and cash-equivalents deposited in financial institutions in amounts which, from time to time, may exceed federal insurance limits. However, based on the current Federal Deposit Insurance Coverage management believes that the Institute does not face a significant risk of loss on these accounts that might result from the failures of the financial institutions.

NOTE L - FINANCIAL INVESTMENT

In 2010, the Institute entered into a joint venture with the Ludwig Institute for Cancer Research Ltd. and formed a U.S. company named Cancer Vaccine Acceleration Company, LLC ("CVAC"). The members' initial capital contribution was $200. The purpose of the company is to obtain, hold, and develop intellectual property and other assets related to research and development of a vaccine for cancer in furtherance of the respective charitable missions of the members. The Institute believes that at present, the value of this investment is not material.

NOTE M - LEASE OBLIGATION

The Institute is obligated under a lease agreement for office space which expired in August 2017. The lease was amended in 2008 to include additional space, of which a portion had been sublet. In January 2017, the Institute has also entered into a 124-month lease agreement for new office space expiring in January 2028. The lease is subject to escalation for the Institute's pro-rata share of increases in real estate taxes and operating expenses. Concurrent with the authorization of the lease agreement, the Institute entered into a sublease agreement for a portion of its new office space also expiring in January 2028. In September 2017, the Institute entered into lease agreements for office equipment, which expire in September 2022. Minimum future estimated lease payments and lease income are as follows:

Year Ending June 30,	Lease Payments	Lease Income
2020	$ 545,756	$ (126,165)
2021	545,756	(126,165)
2022	545,756	(126,165)
2023	554,071	(134,051)
2024	556,842	(136,679)
Thereafter	1,995,351	(489,766)
Total	$ 4,743,532	$(1,138,991)